A research report has found that growth driven by weight-loss drugs is creating bubble risks for the pharmaceutical industry.
**Key Points**
A Deloitte study reveals that oncology is no longer the largest contributor to late-stage pipeline value for the first time in 16 years. Driven by GLP-1 weight-loss and diabetes drugs, the R&D return rate for the world's top 20 pharmaceutical companies has risen for the third consecutive year, reaching 7%. The overwhelming impact of the weight-loss drug trend is masking weak fundamentals in other areas of the pharmaceutical sector.
**Obesity Drugs Surpass Oncology as Top Source of Pharma R&D Returns**
Recent research indicates that while demand for weight-loss and diabetes medications is soaring and industry profits are surging, the pharmaceutical sector faces the risk of a bubble effect. The intense demand for blockbuster weight-loss drugs has pushed pharmaceutical R&D returns to multi-year highs. However, a report released by Deloitte on Monday points out that these impressive figures obscure operational pressures faced by other therapeutic areas. The R&D return rate for the global top 20 pharmaceutical firms has improved for three straight years, rising to 7%, almost entirely driven by high-potential new drugs like glucagon-like peptide-1 (GLP-1) receptor agonists. The report found that obesity treatments have, for the first time in 16 years, surpassed oncology drugs to become the largest contributor to the value of late-stage pharmaceutical pipelines. Deloitte stated that excessive industry concentration in a single therapeutic area increases companies' vulnerability to unexpected events impacting that specific field. "This is a bubble because industry resources and capital are overly concentrated in one area," said Hanno Ronte, a partner in Deloitte's Life Sciences & Health Care practice, on CNBC's 'Squawk Box Europe'. In the 2025 late-stage pipeline, obesity and diabetes drugs are projected to account for 38% of all anticipated commercial cash flows. The pulling power of GLP-1 drugs is so strong that it completely overshadows the weak performance of the rest of the industry. Excluding GLP-1/GIP related assets, the overall industry R&D return rate is just 2.9%, lower than the 3.8% recorded in 2024.
Data shows that obesity drugs now constitute approximately 25% of the total anticipated sales from late-stage pipelines, while oncology's share has slipped to 20%. As recently as 2022, obesity drugs accounted for only 1% of pipeline expected value, indicating a dramatic shift in the industry landscape. The weight-loss drug frenzy has boosted the industry's overall book growth but also led to high risk concentration. Deloitte estimates that just 54 super-blockbuster new drug indications (representing only 9% of the total late-stage pipeline) will contribute approximately 70% of the risk-adjusted peak sales.
**Sector Concentration Risks Intensify**
While reliance on blockbuster drugs is not new for pharmaceutical companies, the current level of concentration is unprecedented. Deloitte notes that while this structure allows a few new drugs to lift overall investment returns, it also means the industry has become extremely sensitive to competitive shocks and policy fluctuations within this specific niche. "From a patient perspective, this bubble won't burst, and the related drugs won't disappear," Ronte said. "But now the GLP-1 field combines both aesthetic/body-shaping and healthcare attributes, fundamentally reshaping patient demand, healthcare systems, and the entire market landscape." Scientists continue to explore the full potential of GLP-1 drugs. Novo Nordisk's GLP-1 drugs are already approved for reducing cardiovascular risk and treating liver and kidney diseases; Eli Lilly's GLP-1/GIP dual agonist is approved for treating sleep apnea in people with obesity. However, many unknowns remain regarding these drugs, particularly their long-term effects on brain health and systemic inflammation. Last year, Novo Nordisk released results from a multi-year clinical trial investigating whether semaglutide (the core component of its blockbuster diabetes/weight-loss drugs) could slow the progression of Alzheimer's disease. The trial did not meet its primary endpoint of significantly slowing disease progression, but the drug did affect levels of Alzheimer's-related proteins and systemic inflammation markers in patients. Other research has confirmed that GLP-1 based drugs can also aid in the rehabilitation of patients with addiction disorders. "This is precisely why market optimism persists; everyone is still riding this wave of R&D benefits, and capital continues to flow in," Ronte added. "But when too many players crowd into the same space, the room for growth for individual companies becomes very limited."